AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 221 min read$BNTX

Sahin Ugur sold $7.9M of BNTX

Sahin Ugur (Chief Executive Officer) sold 79,000 shares of BioNTech SE (BNTX) at an average of $99.50 ($97.81–$100.72, $7.86M total) across 2 trades over 2026-09-21 to 2026-09-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sahin Ugur
Published Sep 22, 2026, 9:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BNTX
Neutral
medium confidence
Mentioned
$BNTX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BNTXNeutralLow
01

Why it matters

Provides fresh data on insider holdings, useful for short‑term risk assessment.

02

Market read

Direct relevance to BNTX shareholders; limited broader market impact.

03

What to watch

Potential upcoming clinical data releases could offset any negative sentiment from the sale.

Relevance 5/10Novelty 6/10Timing: filing date 2026‑09‑22

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$BNTXNeutralMedium confidence
Context

CEO Sahin Ugur sold 79,000 shares for $7.86M via a 10b5‑1 plan, reducing his stake to 410,209 shares.

Expected impact

Slight downward pressure in the short term.

Evidence & confidence

Sale size is moderate ($7.9M) and executed under a pre‑arranged plan, limiting strong inference.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are common and not sector‑wide.

Regional

No significant regional effect beyond BioNTech's share price.

Global

Limited global relevance; only relevant to investors tracking BioNTech.

Counterpoint

What could challenge this read

The sale could be routine liquidity management; the stock may remain stable.

Key entities

  • person
    Sahin Ugur

    Chief Executive Officer of BioNTech SE

  • company
    BioNTech SE

    German biotech listed on NASDAQ under BNTX

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BNTX insider trading history →

Related articles

SEP 28
$BNTXLow

Three BioNTech plants are shutting down—about 1,800 employees affected

BioNTech plans to close three plants by 2028, affecting 1,800 employees. The closures follow failed sales due to market conditions. The company cites low capacity utilization and a focus on cancer medicine. BioNTech reported a net loss of €1.35 billion in the first half of 2023. Co-founders Sahin and Türeci will leave to form a new company, Arife.

bluewin.ch2 min
SEP 25
$BNTXMedAI 8/10

BioNTech (NasdaqGS:BNTX) Stock May Look Fully Valued On Fresh Lung Cancer Trial Data

BioNTech's stock has fallen 63.3% over 5 years, raising questions about its valuation. Recent Phase 3 lung cancer trial data showed promising results, potentially boosting long-term revenue expectations. The company trades at 8.3x P/S, lower than peers. Analysts are divided on whether the oncology pipeline justifies the current valuation, with bulls seeing 16% undervaluation and bears citing 18% overvaluation due to declining COVID-19 vaccine demand.

simplywall.st2 min
SEP 24
$PFEHighAI 9/10

Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?

Pfizer (PFE) and BioNTech (BNTX) received FDA approval for their updated COVID-19 vaccine, COMIRNATY XFG, targeting the XFG variant. The approval secures their position in seasonal COVID-19 immunizations, providing a stable revenue stream. For Pfizer, this supports cash flow and pipeline investments, while for BioNTech, it validates its mRNA platform and maintains market share. Both companies face risks from potential demand declines and market contraction.

insidermonkey.com2 min